For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial ...

MBX Biosciences (MBX) announced positive results from its Phase 1 single ascending dose, SAD, and multiple ascending dose, MAD, clinical trial ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

Intensive blood pressure control in hypertensive chronic kidney disease (CKD) provides a survival advantage and other benefits.

KEEN to lose weight in 2025? So are almost half of our readers. While weight-loss jabs, similar to Ozempic, boomed in ...

MBX Biosciences, Inc. (MBX) announced Tuesday positive results from its Phase 1 single ascending dose or SAD and multiple ascending ...